These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6283875)

  • 1. Pions, protectors. Examples of a vigorous decade in radiotherapy.
    Kligerman MM
    Am J Clin Oncol; 1982 Apr; 5(2):101-13. PubMed ID: 6283875
    [No Abstract]   [Full Text] [Related]  

  • 2. [Combined use of amifostine and misonidazole in experimental radiotherapy].
    Tsukiyama I
    Nihon Igaku Hoshasen Gakkai Zasshi; 1983 Apr; 43(4):613-21. PubMed ID: 6310492
    [No Abstract]   [Full Text] [Related]  

  • 3. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000-02 phase III randomized trial.
    Bardet E; Martin L; Calais G; Alfonsi M; Feham NE; Tuchais C; Boisselier P; Dessard-Diana B; Seng SH; Garaud P; Aupérin A; Bourhis J
    J Clin Oncol; 2011 Jan; 29(2):127-33. PubMed ID: 21115863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Altmann S; Hoffmanns H
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.
    Anné PR; Curran WJ
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):18-9. PubMed ID: 11917279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amifostine--a radioprotector in locally advanced head and neck tumors.
    Schönekäs KG; Wagner W; Prott FJ
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():27-9. PubMed ID: 10584137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New data on cytoprotection in radiotherapy].
    Sauer R; Strnad V
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():1. PubMed ID: 10584131
    [No Abstract]   [Full Text] [Related]  

  • 8. A new administration schedule for amifostine as a radioprotector in cancer therapy.
    Wagner W; Radmard A; Schönekaes KG
    Anticancer Res; 1999; 19(3B):2281-3. PubMed ID: 10472344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine?
    Peters K; Mücke R; Hamann D; Ziegler PG; Fietkau R
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():23-6. PubMed ID: 10584136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
    Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moist skin care can diminish acute radiation-induced skin toxicity.
    Momm F; Weissenberger C; Bartelt S; Henke M
    Strahlenther Onkol; 2003 Oct; 179(10):708-12. PubMed ID: 14566480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amifostine in the treatment of head and neck cancer: intravenous administration, subcutaneous administration, or none of the above.
    Eisbruch A
    J Clin Oncol; 2011 Jan; 29(2):119-21. PubMed ID: 21115854
    [No Abstract]   [Full Text] [Related]  

  • 14. Amifostine: a radioprotector in locally advanced head and neck tumors.
    Wagner W; Prott FJ; Schonekas KG
    Oncol Rep; 1998; 5(5):1255-7. PubMed ID: 9683846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amifostine as a radioprotectant.
    Gosselin TK; Mautner B
    Clin J Oncol Nurs; 2002; 6(3):175-6, 180. PubMed ID: 11998614
    [No Abstract]   [Full Text] [Related]  

  • 16. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
    Vacha P; Marx M; Engel A; Richter E; Feyerabend T
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
    Braaksma M; Levendag P
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experience in the search of new prolonged-action radiation-protective agents].
    Grachev SA; Sverdlov AG; Kropachev EN; Nikanorova NG; Bondarev GN; Drobchenko SN
    Radiats Biol Radioecol; 1996; 36(2):190-4. PubMed ID: 8673217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].
    Büntzel J; Glatzel M; Schuth J; Weinaug R; Küttner K; Fröhlich D
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():37-40. PubMed ID: 10584140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers.
    Anacak Y; Kamer S; Haydaroglu A
    Pediatr Blood Cancer; 2007 May; 48(5):579-81. PubMed ID: 16395679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.